Freddy Del-Carpio Munoz

Freddy Del-Carpio Munoz

Auto-generated profile, based on publicly available information

Freddy Del-Carpio Munoz

Department of Cardiovascular Medicine Mayo Clinic Rochester Minnesota USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in The American Journal of Cardiology
Verified
Journal Article
Closed access
FMFreddy Del-Carpio Munoz
Freddy Del-Carpio Munoz
SGS. Michael Gharacholou
S. Michael Gharacholou
TMThomas M. Munger
Thomas M. Munger
PFPaul A. Friedman
Paul A. Friedman
SASamuel J. Asirvatham
Samuel J. Asirvatham
PNPeter A. Noseworthy
Peter A. Noseworthy

2 August 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
FEFatima M Ezzeddine
Fatima M Ezzeddine
KAKolade M Agboola
Kolade M Agboola
LHLeslie C Hassett
Leslie C Hassett
AKAmmar M Killu
Ammar M Killu
FMFreddy Del-Carpio Munoz
Freddy Del-Carpio Munoz
KSKonstantinos Siontis
Konstantinos Siontis
Atrial fibrillation (AF) is common in hypertrophic cardiomyopathy (HCM). There is limited data regarding the outcomes of AF catheter ablation in HCM patients. In this study, we aimed to synthesize all available evidence on the effectiveness of ablation of AF in patients with HCM compared to those without HCM. We systematically reviewed bibliographic databases to identify studies published through February 2023. We included cohort studies with available quantitative information on rates of recurrent atrial arrhythmias, anti-arrhythmic drug (AAD) therapy, and repeat ablation procedures after initial AF ablation in patients with vs without HCM. Estimates were combined using random-effects meta-analysis models and reported as risk ratios (RR) and 95% confidence intervals (CI). Eight studies were included in quantitative synthesis (262 HCM and 642 non-HCM patients). During median follow-up 13–54 months across studies, AF recurrence rates ranged from 13.3% to 92.9% in HCM and 7.6% to 58.8% in non-HCM patients. The pooled RR for recurrent atrial arrhythmia after the first AF ablation in HCM patients compared to non-HCM controls was 1.498 (95% CI = 1.305–1.720; P < 0.001). During follow-up, HCM patients more often required AAD therapy (RR = 2.844; 95% CI = 1.713–4.856; P < 0.001) and repeat AF ablation (RR = 1.544; 95% CI = 1.070–2.228; P = 0.02). The pooled RR for recurrent atrial arrhythmias after the last AF ablation was higher in patients with HCM than those without HCM (RR = 1.607; 95% CI = 1.235–2.090; P < 0.001). Compared to non-HCM patients, those with HCM had higher rates of recurrent atrial arrhythmias, AAD use, and need for repeat AF ablation after initial ablation of AF.

1 October 2022 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
ALAdetola Ladejobi
Adetola Ladejobi
GCGeorgios Christopoulos
Georgios Christopoulos
Nicholas Yick Loong TanNicholas Yick Loong Tan
Nicholas Yick Loong Tan
TLThomas P. Ladas
Thomas P. Ladas
JTJason Tri
Jason Tri
FMFreddy Del-Carpio Munoz
Freddy Del-Carpio Munoz
Background: Previous animal studies have shown no significant vascular injury from pulsed electrical field (PEF) ablation. We sought to assess the effect of PEF on swine coronary arteries. Methods: We performed intracoronary and epicardial (near the coronary artery) PEF ablations in swine pretreated with dual antiplatelet and antiarrhythmic therapy. Intracoronary PEF was delivered using MapiT catheters (Biotronik, Berlin), whereas epicardial PEF was delivered using EPT catheters (Boston Scientific, MA). PEF pulse duration was microseconds (Nanoknife 3.0, Angio Dynamics, NY) or nanoseconds (CellFX, Pulse Biosciences, CA). Results: We performed 39 intracoronary ablations in 10 swine and 20 epicardial-pericoronary ablations in 4 separate swine. Intracoronary PEF was delivered at higher energy compared with epicardial PEF (46 [interquartile range, IQR 20–85] J versus 10 [IQR 10–11] J, P < 0.01). Reversible coronary spasm occurred in 49% intracoronary ablations and 45% epicardial ablations ( P =0.80). At the end study, fixed coronary stenosis was demonstrated in 44% intracoronary ablations (80% for microsecond PEF and 18% for nanosecond PEF) and 0% epicardial ablations. Visible hemorrhagic and/or fibrotic myocardial lesions were observed at necropsy with similar frequency between intracoronary and epicardial PEF (45% versus 50%, P =0.70). Nanosecond PEF (49 ablations in 11 swine), when compared with microsecond PEF (10 intracoronary ablations in 3 swine), resulted in lower energy delivery (21 [IQR 10–46] J versus 129 [IQR 24–143] J, P =0.03) and less incidence of fixed coronary stenosis (18% versus 80%, P =0.04). Conclusions: In the swine model, intracoronary PEF resulted both in significant coronary spasm and fixed coronary stenosis. Epicardial PEF, delivered at lower energy, resulted in reversible spasm but no fixed coronary stenosis.

1 September 2022 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
FEFatima M. Ezzeddine
Fatima M. Ezzeddine
KSKonstantinos Siontis
Konstantinos Siontis
JGJohn Giudicessi
John Giudicessi
MAMichael J. Ackerman
Michael J. Ackerman
AKAmmar M. Killu
Ammar M. Killu
FMFreddy Del-Carpio Munoz
Freddy Del-Carpio Munoz
Background: Mitral annular disjunction (MAD) has recently been recognized as an arrhythmogenic entity. Data on the electrophysiological substrate as well as the outcomes of catheter ablation of ventricular arrhythmias in patients with MAD is limited. Methods: Forty patients with MAD (mean age 47±15 years; 70% female) underwent catheter ablation for ventricular arrhythmias. Detailed clinical, electrocardiographic, cardiac imaging, and procedural data were collected. Clinical outcomes were compared between patients who had substrate modification in the MAD area and those who did not. Results: Twenty-three (57.5%) patients had ablation for premature ventricular contractions, 10 (25%) patients for sustained ventricular tachycardia, and 7 (17.5%) patients for premature ventricular contraction-triggered ventricular fibrillation. Mean end-systolic MAD length was 10.58±3.49 mm on transthoracic echocardiography. Seventeen (42.5%) patients had preprocedural cardiac magnetic resonance imaging, and 5 (29%) patients had late gadolinium enhancement. Among the 18 (45%) patients who had abnormal local electrograms (low voltage, long-duration, fractionated, isolated mid-diastolic potentials) during electroanatomical mapping, 10 (25%) patients had abnormal electrograms in the anterolateral mitral annulus and/or MAD area. Substrate modification was performed in 10 (25%) patients. Catheter ablation was acutely successful in 36 (90%) patients (elimination of premature ventricular contraction or noninducibility of ventricular tachycardia). After a median follow-up duration of 54.08 (interquartile range, 10.67–89.79) months, premature ventricular contraction burden decreased from a median of 9.75% (interquartile range, 3.25–14) before the ablation to a median of 4% (interquartile range, 1–7.75) after the ablation ( P =0.03 [95% CI, 0.055–6.5]). Eight (20.5%) patients had repeat ablation for ventricular arrhythmias. Substrate modification of the MAD was associated with a trend toward lower rates of repeat ablation (0% versus 26.7%; P =0.16). Conclusions: Patients with MAD have a complex arrhythmogenic substrate, and catheter ablation is effective in reducing recurrence of ventricular arrhythmias. Substrate mapping and ablation may be considered in these patients.

30 June 2022 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Closed access
PDF file
NTNicholas Y. Tan
Nicholas Y. Tan
TLThomas P. Ladas
Thomas P. Ladas
GCGeorgios Christopoulos
Georgios Christopoulos
ASAlan M. Sugrue
Alan M. Sugrue
MZMartin van Zyl
Martin van Zyl
FMFreddy Del-Carpio Munoz
Freddy Del-Carpio Munoz

28 December 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
JCJingjing Chen
Jingjing Chen
FEFatima M Ezzeddine
Fatima M Ezzeddine
XLXiaoke Liu
Xiaoke Liu
FMFreddy Del-Carpio Munoz
Freddy Del-Carpio Munoz
PFPaul Friedman
Paul Friedman
YCYong-Mei Cha
Yong-Mei Cha
Artificial intelligence (AI)-enabled electrocardiogram (ECG) has proved to be a valuable screening tool for identifying individuals with reduced left ventricular ejection fraction (LVEF).1 At Mayo Clinic, we have successfully developed and integrated an AI algorithm into our 12-lead ECG dashboard, facilitating early and non-invasive detection of reduced LVEF.2–4 The objective of this report was to apply our recently developed AI-ECG algorithm in patients who underwent left bundle branch area pacing (LBBAP) to predict cardiac resynchronization therapy (CRT) outcomes in patients with heart failure and reduced ejection fraction (LVEF ≤ 50%).